Get started

Financials · IOVA

Iovance Biotherapeutics Inc. (IOVA) financials

For the twelve months ended Sep 30, 2026, Iovance Biotherapeutics Inc. reported $378.98M of revenue and -$220.53M of net income.

Revenue, TTM
$378.98M
Revenue growth, YoY
+51.3%
Net income, TTM
-$220.53M
Net margin
-58.2%
Free cash flow, TTM
-$216.06M
Cash
$57.93M
P/S
9.97
Market cap
$3.78B
Annual revenue$263.50M
FY2016FY2025
Annual net income-$390.98M
FY2016FY2025
Annual free cash flow-$336.24M
FY2016FY2025

IOVA revenue and earnings growth

IOVA revenueQ3 2026$121.47M

Quarter YoY
+80.1%
QoQ
+22.3%
FY YoY
+60.6%

IOVA revenue was $121.47M in fiscal Q3 2026 (ended Sep 30, 2026), up 80.1% from a year earlier and up 22.3% from the prior quarter. For the full fiscal 2025 it was $263.50M, up 60.6% from fiscal 2024. Fiscal 2025 is the highest of the 9 fiscal years on file.

IOVA net incomeQ3 2026-$22.27M

IOVA net income was -$22.27M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$91.25M a year earlier. For the full fiscal 2025 it was -$390.98M, compared with -$372.18M in fiscal 2024.

IOVA EPSQ3 2026-$0.05

IOVA diluted EPS was -$0.05 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.25 a year earlier. For the full fiscal 2025 it was -$1.09, compared with -$1.28 in fiscal 2024.

IOVA free cash flowQ3 2026-$9.21M

IOVA free cash flow was -$9.21M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$89.55M a year earlier. For the full fiscal 2025 it was -$336.24M, compared with -$364.05M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$263.50M$164.07M$1.19M----$0$0$0
Cost of revenue$173.18M$93.25M$1.03M-------
Gross profit$90.32M$70.82M$156.0K-------
Research and development$300.27M$276.23M$333.19M$294.78M$259.04M$201.73M$166.02M$99.83M$71.61M$26.94M
Selling, general and admin$152.32M$152.27M$106.10M$104.10M$83.66M$60.21M$40.85M$28.43M$21.26M$26.70M
Operating income-$403.36M-$395.28M-$460.56M-$398.88M-$342.70M-$261.94M-$206.87M-$128.26M-$92.88M-$53.64M
Pre-tax income-$393.05M-$375.00M-$447.52M-$395.89M-$342.25M-----
Income tax-$2.07M-$2.83M-$3.48M$0$0$0$0$0$0$0
Net income-$390.98M-$372.18M-$444.04M-$395.89M-$342.25M-$259.58M-$197.56M-$123.58M-$92.06M-$52.89M
EPS, basic-$1.09-$1.28-$1.89-$2.49-$2.23-$1.88-$1.59-$1.27-$1.41-$1.85
EPS, diluted-$1.09-$1.28-$1.89-$2.49-$2.23-$1.88-$1.59-$1.27-$1.41-$1.85
Diluted shares357,345289,877235,131159,259153,406138,301124,33697,27765,24255,268

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$163.08M$122.05M$114.89M$238.16M$84.31M$72.85M$19.42M$82.15M$145.37M$106.72M
Short-term investments$133.90M$208.09M$164.98M$240.11M$426.18M$562.11M$293.11M$386.37M--
Receivables$82.45M$69.34M$151.0K-------
Inventory$51.68M$51.52M$10.37M-------
Current assets$442.69M$457.02M$307.85M$479.12M$507.96M$636.10M$316.49M$475.37M$149.29M$169.51M
Total assets$913.17M$910.43M$780.35M$663.98M$777.33M$768.46M$344.65M$480.82M$155.37M$171.89M
Current liabilities$138.36M$122.34M$110.31M$91.48M$89.20M$54.87M$39.08M$14.40M$9.60M$4.97M
Total liabilities$214.59M$200.02M$195.74M$164.34M$155.67M$111.96M$45.68M$14.63M$9.89M-
Shareholders' equity$698.58M$710.40M$584.61M$499.64M$621.66M$656.50M$298.97M$466.19M$145.48M$166.92M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$302.41M-$352.98M-$361.82M-$292.76M-$227.94M-$205.13M-$158.89M-$101.25M-$78.71M-$32.67M
Capital expenditures$33.84M$11.07M$22.29M$20.43M$37.57M$46.79M$6.92M$1.20M$1.03M$1.52M
Free cash flow-$336.24M-$364.05M-$384.11M-$313.18M-$265.51M-$251.93M-$165.81M-$102.45M-$79.74M-$34.19M
Investing cash flow$47.50M-$96.41M-$155.24M$256.45M$132.0K-$317.85M$90.03M-$386.28M$58.68M$8.89M
Financing cash flow$300.77M$390.66M$462.96M$190.15M$239.27M$576.42M$6.13M$424.31M$58.69M$96.90M
Stock-based compensation$61.58M$109.63M$62.63M$84.02M$69.77M$40.89M$24.28M$20.03M$11.97M$18.90M
Depreciation and amortization$12.86M$11.26M$11.57M$9.31M$3.11M$1.14M$1.17M$956.0K$952.0K$978.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY60.6%13699.0%--------
Gross margin34.3%43.2%13.1%-------
Operating margin-153.1%-240.9%-38735.0%-------
Net margin-148.4%-226.8%-37345.4%-------
Free cash flow margin-127.6%-221.9%-32305.3%-------
Return on equity-56.0%-52.4%-76.0%-79.2%-55.1%-39.5%-66.1%-26.5%-63.3%-31.7%
Return on assets-42.8%-40.9%-56.9%-59.6%-44.0%-33.8%-57.3%-25.7%-59.3%-30.8%
Current ratio3.203.742.795.245.6911.598.1033.0215.5634.12

Source: XBRL data Iovance Biotherapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IOVA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IOVA$378.98M+51.3%-$220.53M-58.2%$3.78B
TIL$8.97M+2.5%-$30.28M-337.7%$43.9M
IMTX---€196.45M-$962.1M
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
BMY$50.03B+4.2%$9.24B18.5%$127.01B
AUTL$117.39M+292.2%-$280.16M-238.7%$351.3M

IOVA FAQ

8 questions
  • What is IOVA revenue?
    Iovance Biotherapeutics Inc. (IOVA) reported $378.98M of revenue for the twelve months ended Sep 30, 2026. That is up 51.3% from the year before. Revenue for fiscal 2025 was $263.50M.
  • Is IOVA profitable?
    No. Iovance Biotherapeutics Inc. reported a net loss of $220.53M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does IOVA have?
    Iovance Biotherapeutics Inc. reported $57.93M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is IOVA revenue growing?
    Iovance Biotherapeutics Inc.'s revenue changed +60.6% in fiscal 2025, to $263.50M.
  • What is IOVA gross margin?
    Iovance Biotherapeutics Inc.'s gross profit was $201.75M on $378.98M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 53.2%.
  • What is IOVA free cash flow?
    Iovance Biotherapeutics Inc. generated -$216.06M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$189.95M less capital expenditures.
  • When did IOVA last report financial results?
    The latest statements here come from Iovance Biotherapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this IOVA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Iovance Biotherapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.